---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40228780.md"
description: "$Novo Nordisk AS(NVO.US) In the weight loss field, the blockbuster GLP-1 product is already out there, meeting the achievable weight loss goals for most people. Whatever comes next, be it dual-target drugs or any combination of active agents, must develop towards being safer, more convenient, lower-priced, and more durable to have a future. Therefore, subsequent head-to-head trial results showing a few percentage points more weight loss speed than GLP-1 are almost meaningless. The essence of weight loss is achieved through "hunger" combined with physical activity.Novo Nordisk's oral semaglutide formulation in this field almost meets the three requirements of being safer, more convenient, and lower-priced. However, this type of medication requires long-term use, treating weight loss as chronic disease management. Once stopped, rebound occurs. There are currently no good options for achieving greater durability. Overall, oral semaglutide is the current optimal choice."
datetime: "2026-04-27T14:12:17.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40228780.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40228780.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40228780.md)
author: "[诺和诺德研发部](https://longbridge.com/en/profiles/21918652.md)"
---

# $Novo Nordisk AS(NVO.US) In the weight loss field,…


### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)